Li Kang Biomedical Co Ltd (6242) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.077x

Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has a cash flow conversion efficiency ratio of 0.077x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$67.23 Million ≈ $2.12 Million USD) by net assets (NT$871.24 Million ≈ $27.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Li Kang Biomedical Co Ltd to measure how many days the company can operate on defensive assets alone.

Li Kang Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)

This chart illustrates how Li Kang Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Li Kang Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Cyclone Metals Ltd AU:CLE	-0.088x
Shriro Holdings Ltd AU:SHM	0.205x
Speed Rabbit Pizza SA PA:MLSRP	N/A
Ledlink Optics TWO:5230	0.045x
Brunswick Exploration Inc V:BRW	-0.040x
Piolink Inc KQ:170790	0.042x
Veru Inc NASDAQ:VERU	-0.166x
Theradiag SA PA:ALTHE	1.404x

Annual Cash Flow Conversion Efficiency for Li Kang Biomedical Co Ltd (2002–2025)

The table below shows the annual cash flow conversion efficiency of Li Kang Biomedical Co Ltd from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see 6242 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$871.24 Million ≈ $27.45 Million	NT$92.15 Million ≈ $2.90 Million	0.106x	+38.42%
2024-12-31	NT$855.68 Million ≈ $26.96 Million	NT$65.38 Million ≈ $2.06 Million	0.076x	-50.24%
2023-12-31	NT$630.03 Million ≈ $19.85 Million	NT$96.74 Million ≈ $3.05 Million	0.154x	-44.32%
2022-12-31	NT$570.14 Million ≈ $17.96 Million	NT$157.24 Million ≈ $4.95 Million	0.276x	+124.49%
2021-12-31	NT$492.00 Million ≈ $15.50 Million	NT$60.45 Million ≈ $1.90 Million	0.123x	-23.53%
2020-12-31	NT$508.30 Million ≈ $16.01 Million	NT$81.67 Million ≈ $2.57 Million	0.161x	-16.08%
2019-12-31	NT$483.44 Million ≈ $15.23 Million	NT$92.56 Million ≈ $2.92 Million	0.191x	-15.29%
2018-12-31	NT$466.92 Million ≈ $14.71 Million	NT$105.53 Million ≈ $3.32 Million	0.226x	-8.94%
2017-12-31	NT$445.68 Million ≈ $14.04 Million	NT$110.61 Million ≈ $3.48 Million	0.248x	-23.67%
2016-12-31	NT$340.80 Million ≈ $10.74 Million	NT$110.82 Million ≈ $3.49 Million	0.325x	+42.61%
2015-12-31	NT$280.29 Million ≈ $8.83 Million	NT$63.91 Million ≈ $2.01 Million	0.228x	+24.49%
2014-12-31	NT$227.44 Million ≈ $7.17 Million	NT$41.66 Million ≈ $1.31 Million	0.183x	-18.77%
2009-12-31	NT$128.49 Million ≈ $4.05 Million	NT$28.97 Million ≈ $912.65K	0.225x	+1252.82%
2003-12-31	NT$338.06 Million ≈ $10.65 Million	NT$5.63 Million ≈ $177.50K	0.017x	-87.37%
2002-12-31	NT$347.64 Million ≈ $10.95 Million	NT$45.87 Million ≈ $1.45 Million	0.132x	--

About Li Kang Biomedical Co Ltd

TWO:6242 Taiwan Travel Services

Market Cap

$36.78 Million

NT$1.17 Billion TWD

Market Cap Rank

#23103 Global

#1450 in Taiwan

Share Price

NT$36.70

Change (1 day)

+0.55%

52-Week Range

NT$36.15 - NT$42.95

All Time High

NT$13364.93